Autopsy report · NCT00137865

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Sponsor decided to terminate the study early so they could begin a second dose-escalation study of EGEN-001 in combination with standard chemotherapy.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 2 months before it stopped.
18 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: EGEN, Inc.
Sponsor type: Industry
Conditions: Ovarian Neoplasms
Interventions: EGEN-001 (phIL-12-005/PPC)
Participants: 18
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.